Protalix BioTherapeutics, Inc. (PLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q1 '10: 1.1M Q2 '10: 1.1M Q3 '10: 3.2M Q4 '10: 1.2M Q1 '11: 4.1M Q2 '11: 764K Q3 '11: 1.1M Q4 '11: 2.4M Q1 '12: 3.9M Q2 '12: 26.1M Q3 '12: 3.7M Q4 '12: 1.2M Q1 '13: 3.6M Q2 '13: 2.3M Q3 '13: 2.3M Q1 '14: 6.7M Q2 '14: 2.4M Q3 '14: 2.4M Q1 '15: 1.7M Q2 '15: 1.3M Q3 '15: 1.3M Q4 '15: 0 Q1 '16: 679K Q2 '16: 1.8M Q3 '16: 4.7M Q4 '16: 2.1M Q1 '17: 2.9M Q2 '17: 6.4M Q3 '17: 7.5M Q4 '17: 4.3M Q1 '18: 4.6M Q2 '18: 2M Q3 '18: 663K Q4 '18: 27M Q1 '19: 10.4M Q2 '19: 12.2M Q3 '19: 14.2M Q4 '19: 17.8M Q1 '20: 21.6M Q2 '20: 11M Q3 '20: 10.8M Q4 '20: 19.5M Q1 '21: 11.3M Q2 '21: 6.4M Q3 '21: 12.1M Q4 '21: 8.5M Q1 '22: 16.1M Q2 '22: 8.8M Q3 '22: 14.2M Q4 '22: 8.6M Q1 '23: 9.6M Q2 '23: 35.1M Q3 '23: 10.3M Q4 '23: 10.5M Q1 '24: 3.7M Q2 '24: 13.5M Q3 '24: 18M Q4 '24: 18.2M Q1 '25: 10.1M Q2 '25: 15.7M Q3 '25: 17.9M Q4 '25: 9.1M Q1 '26: 33.8M Q2 '26: 19.9M Q4 '11 Q1 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit Quarterly

-8M 0 8M 16M 24M Q1 '10: 847K Q2 '10: 613K Q3 '10: 2.1M Q4 '10: 3.3M Q1 '11: 5.2M Q2 '11: -4.8M Q3 '11: 677K Q4 '11: 294K Q1 '12: 2.4M Q2 '12: 22M Q3 '12: 3M Q4 '12: -1.1M Q1 '13: 3M Q2 '13: 1.7M Q3 '13: 1.8M Q1 '14: 3.3M Q2 '14: 1.1M Q3 '14: 1.9M Q1 '15: 1.4M Q2 '15: 1.1M Q3 '15: 1.1M Q4 '15: 0 Q1 '16: 156K Q2 '16: 94K Q3 '16: 422K Q4 '16: 129K Q1 '17: 801K Q2 '17: 835K Q3 '17: 1.5M Q4 '17: 915K Q1 '18: 1.6M Q2 '18: -177K Q3 '18: -1.3M Q3 '10 Q4 '11 Q1 '13 Q3 '14 Q1 '16 Q2 '17 Q3 '18

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '10: -8.1M Q2 '10: -10.2M Q3 '10: -2.8M Q4 '10: -8.8M Q1 '11: -5M Q2 '11: -13.9M Q3 '11: -8.8M Q4 '11: -8.9M Q1 '12: -6.1M Q2 '12: 9.6M Q3 '12: -5.6M Q4 '12: -10.2M Q1 '13: -4.4M Q2 '13: -6.9M Q3 '13: -5.6M Q4 '13: -17.1M Q1 '14: -6.5M Q2 '14: -5.4M Q3 '14: -6.2M Q4 '14: -10.4M Q1 '15: -5.4M Q2 '15: -5.6M Q3 '15: -5M Q4 '15: -7.7M Q1 '16: -7.9M Q2 '16: -9.9M Q3 '16: -6.6M Q4 '16: -8.7M Q1 '17: -6.4M Q2 '17: -10.8M Q3 '17: -7.8M Q4 '17: -9.6M Q1 '18: -5.2M Q2 '18: -6.7M Q3 '18: -3.7M Q4 '18: -3.7M Q1 '19: -5.5M Q2 '19: -5.8M Q3 '19: -1.5M Q4 '19: 2.2M Q1 '20: 4.7M Q2 '20: -2.2M Q3 '20: -2.6M Q4 '20: 2.8M Q1 '21: -3.7M Q2 '21: -9.2M Q3 '21: -1.9M Q4 '21: -5.7M Q1 '22: -1.9M Q2 '22: -5.5M Q3 '22: -3.1M Q4 '22: -2.5M Q1 '23: -2.5M Q2 '23: 20.4M Q3 '23: -1.9M Q4 '23: -5.6M Q1 '24: -4.9M Q2 '24: -2.4M Q3 '24: 4M Q4 '24: 7.2M Q1 '25: -4.1M Q2 '25: 1.2M Q3 '25: 2.1M Q4 '25: -4.7M Q1 '26: 21.1M Q2 '26: 4.7M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '10: -8M Q2 '10: -10M Q3 '10: -2.5M Q4 '10: -8.5M Q1 '11: -5.1M Q2 '11: -13.7M Q3 '11: -8.9M Q4 '11: -8.9M Q1 '12: -5.9M Q2 '12: 9.6M Q3 '12: -5.5M Q4 '12: -9.9M Q1 '13: -4.3M Q2 '13: -6.8M Q3 '13: -5.7M Q4 '13: -10.9M Q1 '14: -7.3M Q2 '14: -6.1M Q3 '14: -8M Q4 '14: -8.5M Q1 '15: -6M Q2 '15: -5.1M Q3 '15: -3.8M Q4 '15: 72.9M Q1 '16: -8.6M Q2 '16: -10.9M Q3 '16: -7.3M Q4 '16: -2.6M Q1 '17: -59.1M Q2 '17: 450K Q3 '17: -11.4M Q4 '17: -13.3M Q1 '18: -7.2M Q2 '18: -8.5M Q3 '18: -5.3M Q4 '18: -5.4M Q1 '19: -7.3M Q2 '19: -7.7M Q3 '19: -3.6M Q4 '19: 291K Q1 '20: 1.7M Q2 '20: -4.2M Q3 '20: -4.4M Q4 '20: 397K Q1 '21: -5.5M Q2 '21: -11.2M Q3 '21: -4.2M Q4 '21: -6.7M Q1 '22: -2.3M Q2 '22: -5.3M Q3 '22: -3.6M Q4 '22: -3.7M Q1 '23: -3.1M Q2 '23: 19.3M Q3 '23: -1.9M Q4 '23: -6M Q1 '24: -4.6M Q2 '24: -2.2M Q3 '24: 3.2M Q4 '24: 6.5M Q1 '25: -3.6M Q2 '25: 164K Q3 '25: 2.4M Q4 '25: -5.5M Q1 '26: 18.3M Q2 '26: 3.8M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

0 3.5M 7M 10.5M Q2 '10: 0 Q1 '11: 778K Q2 '11: 132K Q3 '11: 220K Q4 '11: 395K Q1 '12: 1.3M Q2 '12: 3.3M Q3 '12: 2.4M Q4 '12: 1.2M Q1 '13: 971K Q2 '13: 1.3M Q3 '13: 1.6M Q1 '14: 4.1M Q2 '14: 1.6M Q3 '14: 1.8M Q1 '15: 282K Q2 '15: 225K Q3 '15: 223K Q4 '15: 0 Q1 '16: 523K Q2 '16: 1.7M Q3 '16: 4.2M Q4 '16: 2M Q1 '17: 2.1M Q2 '17: 5.5M Q3 '17: 6.1M Q4 '17: 1.6M Q1 '18: 2.9M Q2 '18: 2.2M Q3 '18: 1.9M Q4 '18: 2.3M Q1 '19: 2M Q2 '19: 2.7M Q3 '19: 3.2M Q4 '19: 3M Q1 '20: 3.4M Q2 '20: 1.8M Q3 '20: 2.9M Q4 '20: 2.8M Q1 '21: 4.8M Q2 '21: 4.7M Q3 '21: 3.7M Q4 '21: 3.1M Q1 '22: 6M Q2 '22: 4.1M Q3 '22: 7.1M Q4 '22: 2.4M Q1 '23: 3.1M Q2 '23: 6.1M Q3 '23: 4.9M Q4 '23: 8.9M Q1 '24: 2.6M Q2 '24: 9.5M Q3 '24: 8.4M Q4 '24: 3.9M Q1 '25: 8.2M Q2 '25: 5.9M Q3 '25: 8.3M Q4 '25: 4.6M Q1 '26: 4.1M Q2 '26: 7.8M Q4 '11 Q1 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating Cash Flow Quarterly

-16M -8M 0 8M 16M 24M Q3 '10: -9.7M Q4 '10: -8M Q1 '11: -4M Q2 '11: -4.8M Q3 '11: -8.1M Q4 '11: -6.6M Q1 '12: -6.3M Q2 '12: 13.1M Q3 '12: -8M Q4 '12: 1.8M Q1 '13: -9.6M Q2 '13: -8.1M Q3 '13: -8.2M Q4 '13: -4.7M Q1 '14: -8.3M Q2 '14: -6.5M Q3 '14: -9.5M Q4 '14: -4.7M Q1 '15: -6.4M Q2 '15: -5.3M Q3 '15: -8.7M Q4 '15: -3.9M Q1 '16: -9.6M Q2 '16: -11.7M Q3 '16: -3.4M Q4 '16: -7.3M Q1 '17: -8.4M Q2 '17: -8.6M Q3 '17: -10.5M Q4 '17: 17.6M Q1 '18: -9.4M Q2 '18: -8M Q3 '18: 13.6M Q4 '18: -4M Q1 '19: -7.3M Q2 '19: -5.2M Q3 '19: -3.2M Q4 '19: -3.7M Q1 '20: -7.1M Q2 '20: -7.8M Q3 '20: -3.6M Q4 '20: -7.5M Q1 '21: -9.8M Q2 '21: 6.5M Q3 '21: -1.9M Q4 '21: -5.1M Q1 '22: -5.8M Q2 '22: -7.4M Q3 '22: -9.2M Q4 '22: -2.6M Q1 '23: -3M Q2 '23: 5M Q3 '23: -6.9M Q4 '23: 3.6M Q1 '24: 4.2M Q2 '24: -3.6M Q3 '24: 4.1M Q4 '24: 4M Q1 '25: -5.1M Q2 '25: -5.2M Q3 '25: -3.7M Q4 '25: 2M Q1 '26: 22M Q2 '26: -10.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-16M -8M 0 8M 16M 24M Q3 '10: -11M Q4 '10: -9.1M Q1 '11: -6.6M Q2 '11: -6.2M Q3 '11: -9.1M Q4 '11: -7.3M Q1 '12: -7.1M Q2 '12: 12.9M Q3 '12: -8.8M Q4 '12: 1.6M Q1 '13: -10.2M Q2 '13: -8.8M Q3 '13: -8.5M Q4 '13: -5M Q1 '14: -8.6M Q2 '14: -6.6M Q3 '14: -9.8M Q4 '14: -4.9M Q1 '15: -6.5M Q2 '15: -5.6M Q3 '15: -8.8M Q4 '15: -3.9M Q1 '16: -9.9M Q2 '16: -12M Q3 '16: -3.6M Q4 '16: -7.5M Q1 '17: -8.6M Q2 '17: -8.9M Q3 '17: -10.7M Q4 '17: 17.3M Q1 '18: -9.7M Q2 '18: -8.1M Q3 '18: 13.5M Q4 '18: -4.2M Q1 '19: -7.4M Q2 '19: -5.2M Q3 '19: -3.6M Q4 '19: -3.7M Q1 '20: -7.2M Q2 '20: -8M Q3 '20: -3.7M Q4 '20: -7.8M Q1 '21: -10.2M Q2 '21: 6.2M Q3 '21: -2.2M Q4 '21: -5.5M Q1 '22: -6.1M Q2 '22: -7.5M Q3 '22: -9.3M Q4 '22: -2.8M Q1 '23: -3.2M Q2 '23: 4.8M Q3 '23: -7.3M Q4 '23: 3.3M Q1 '24: 3.6M Q2 '24: -3.8M Q3 '24: 4M Q4 '24: 3.6M Q1 '25: -5.4M Q2 '25: -5.7M Q3 '25: -4.2M Q4 '25: 1.6M Q1 '26: 21.3M Q2 '26: -11M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '11: 85.6M Q2 '12: 94.9M Q2 '13: 92.3M Q2 '16: 99.8M Q2 '17: 192.6M Q2 '18: 146.6M Q3 '20: 32.9M Q1 '21: 39.9M Q2 '21: 45.4M Q3 '21: 45.6M Q1 '22: 45.8M Q2 '22: 47.3M Q3 '22: 49.5M Q1 '23: 57.5M Q2 '23: 83.2M Q3 '23: 83.8M Q1 '24: 73M Q2 '24: 73.3M Q3 '24: 81.2M Q1 '25: 76.6M Q2 '25: 81.3M Q3 '25: 80.8M Q1 '26: 83M Q2 '26: 82.6M Q2 '13 Q2 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '10: -0.36 Q1 '11: -0.40 Q2 '11: -0.68 Q3 '11: -0.81 Q4 '11: -0.60 Q1 '12: -0.59 Q2 '12: -0.33 Q3 '12: -0.17 Q4 '12: 0.08 Q1 '13: 0.06 Q2 '13: -0.11 Q3 '13: -0.23 Q4 '13: -0.20 Q1 '14: -0.17 Q2 '14: -0.17 Q3 '14: -0.20 Q4 '14: -0.17 Q1 '15: -0.31 Q2 '15: -0.29 Q3 '15: -0.24 Q4 '15: 0.62 Q1 '16: 0.59 Q2 '16: 0.53 Q3 '16: 0.50 Q4 '16: -0.29 Q1 '17: -0.68 Q2 '18: -6.02 Q3 '18: -5.97 Q4 '18: -0.55 Q1 '19: -1.00 Q2 '19: -1.46 Q3 '19: -1.66 Q4 '19: -1.24 Q1 '20: -0.64 Q2 '20: -0.25 Q3 '20: -0.15 Q4 '20: -0.22 Q1 '21: -0.46 Q2 '21: -0.58 Q3 '21: -0.53 Q4 '21: -0.62 Q1 '22: -0.53 Q2 '22: -0.39 Q3 '22: -0.37 Q4 '22: -0.30 Q1 '23: -0.30 Q2 '23: 0.02 Q3 '23: 0.05 Q4 '23: 0.09 Q1 '24: 0.08 Q2 '24: -0.16 Q3 '24: -0.09 Q4 '24: 0.04 Q1 '25: 0.05 Q2 '25: 0.08 Q3 '25: 0.08 Q4 '25: -0.09 Q1 '26: 0.18 Q2 '26: 0.23 Q2 '11 Q2 '13 Q2 '15 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.